{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=10", "query": { "condition": "Relapse Leukemia", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 1826, "total_pages": 183, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse+Leukemia&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T11:34:02.960Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00588809", "title": "Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Promyelocytic Leukemia (M3)", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia" ], "interventions": [ { "name": "selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2007-12", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-08-05", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00588809" }, { "nct_id": "NCT00005092", "title": "Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Psoralen", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "In vitro-treated peripheral blood stem cell transplantation (PBSCT)", "type": "PROCEDURE" }, { "name": "Radiation Therapy (RT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "49 Years", "sex": "ALL", "summary": "Up to 49 Years" }, "enrollment_count": 7, "start_date": "1999-05-28", "completion_date": "2002-08-28", "has_results": false, "last_update_posted_date": "2018-10-26", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 3, "location_summary": "Chicago, Illinois • St Louis, Missouri • Houston, Texas", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005092" }, { "nct_id": "NCT01319864", "title": "POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory AML", "Relapsed/Refractory ALL", "Secondary AML/MDS", "Acute Leukemia of Ambiguous Lineage", "AML", "ALL" ], "interventions": [ { "name": "Plerixafor Dose Escalation", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "29 Years", "sex": "ALL", "summary": "3 Years to 29 Years" }, "enrollment_count": 20, "start_date": "2011-03", "completion_date": "2016-06-28", "has_results": false, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Denver, Colorado • Atlanta, Georgia + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01319864" }, { "nct_id": "NCT06943872", "title": "A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2025-06-11", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 39, "location_summary": "Laguna Hills, California • Orange, California • Palo Alto, California + 35 more", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06943872" }, { "nct_id": "NCT01743807", "title": "Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Acute Lymphoblastic Leukemia", "Relapsed Acute Myelogenous Leukemia" ], "interventions": [ { "name": "GNKG168", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 4, "start_date": "2014-03-26", "completion_date": "2014-07-28", "has_results": true, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 3, "location_summary": "Los Angeles, California • Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01743807" }, { "nct_id": "NCT02238522", "title": "Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoproliferative Malignancies", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "ZEN003365", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zenith Epigenetics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-10", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2014-11-13", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 4, "location_summary": "St Louis, Missouri • New York, New York • Springfield, Oregon + 1 more", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Springfield", "state": "Oregon" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02238522" }, { "nct_id": "NCT00101231", "title": "Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Basophilic Leukemia", "Adult Acute Eosinophilic Leukemia", "Adult Acute Megakaryoblastic Leukemia (M7)", "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)", "Adult Acute Monoblastic Leukemia (M5a)", "Adult Acute Monocytic Leukemia (M5b)", "Adult Acute Myeloblastic Leukemia With Maturation (M2)", "Adult Acute Myeloblastic Leukemia Without Maturation (M1)", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Acute Myelomonocytic Leukemia (M4)", "Adult Erythroleukemia (M6a)", "Adult Pure Erythroid Leukemia (M6b)", "Blastic Phase Chronic Myelogenous Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Relapsing Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "alvocidib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 88, "start_date": "2004-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-04", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101231" }, { "nct_id": "NCT01787474", "title": "Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2014-05-19", "completion_date": "2021-06-17", "has_results": false, "last_update_posted_date": "2021-06-21", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01787474" }, { "nct_id": "NCT03160079", "title": "Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-Cell Acute Lymphoblastic Leukemia, Adult" ], "interventions": [ { "name": "blinatumomab", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2017-08-04", "completion_date": "2023-06-23", "has_results": true, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 4, "location_summary": "Clovis, California • La Jolla, California • Orange, California + 1 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03160079" }, { "nct_id": "NCT02109627", "title": "Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Relapsed Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ficlatuzumab", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "C. Babis Andreadis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2015-05-01", "completion_date": "2019-12-02", "has_results": false, "last_update_posted_date": "2020-03-24", "last_synced_at": "2026-11-07T11:34:02.960Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02109627" } ] }